SEC Form 4 · accession 0001209191-16-099587
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert F Byrnes
Director
Period of report
Feb 12, 2016
Accepted (ET)
Feb 17, 2016 · 8:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 12, 2016 | M | 4,000 | $6.60 | A | 4,000 | D | |
| Common Stock | Feb 12, 2016 | M | 1,666 | $2.55 | A | 5,666 | D | |
| Common Stock | Feb 12, 2016 | M | 5,333 | $2.55 | A | 10,999 | D | |
| Common Stock | holding | — | — | — | 2,666 | I | By The Byrnes Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.60 | Feb 12, 2016 | M | 4,000 | D | — | Sep 18, 2016 | Common Stock | 4,000 | 0 | D |
| Stock Option (Right to Buy)F2 | $2.55 | Feb 12, 2016 | M | 1,666 | D | — | Jul 20, 2020 | Common Stock | 1,666 | 0 | D |
| Stock Option (Right to Buy)F3 | $2.55 | Feb 12, 2016 | M | 5,333 | D | — | Apr 29, 2018 | Common Stock | 5,333 | 0 | D |
Explanation of responses
- F1The Option was fully vested as of September 19, 2010.
- F2The Option was fully vested as of January 1, 2014.
- F3The Option was fully vested as of January 1, 2012.